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Aims Acute coronary syndromes (ACSs) are driven by inflammationwithin coronary plaque. Interleukin-1 (IL-1) has an estab-
lished role in atherogenesis and the vessel-response to injury. ACS patients have raised serummarkers of inflammation.
We hypothesized that if IL-1 is a driving influence of inflammation in non-ST elevation ACS (NSTE-ACS), IL-1 inhibition
would reduce the inflammatory response at the time of ACS.
Methods
and results
A phase II, double-blinded, randomized, placebo-controlled, study recruited 182 patients with NSTE-ACS, presenting
,48 h from onset of chest pain. Treatment was 1:1 allocation to daily, subcutaneous IL-1receptor antagonist (IL-1ra)
or placebo for 14 days. Baseline characteristics were well matched. Treatment compliance was 85% at 7 days. The
primary endpoint (area-under-the-curve for C-reactive protein over the first 7 days) was: IL-1ra group, 21.98 mg day/L
(95%CI 16.31–29.64); placebo group, 43.5 mg day/L (31.15–60.75) (geometric mean ratio ¼ 0.51 mg/L; 95%CI
0.32–0.79; P ¼ 0.0028). In the IL-1ra group, 14-day achieved high-sensitive C-reactive protein (P, 0.0001) and IL-6
levels (P ¼ 0.02) were lower than Day 1. Sixteen days after discontinuation of treatment (Day 30) high-sensitive
C-reactive protein levels had risen again in the IL-1ra group [IL-1ra; 3.50 mg/L (2.65–4.62): placebo; 2.21 mg/L (1.67–
2.92), P ¼ 0.022]. MACE at Day 30 and 3 months was similar but at 1 year there was a significant excess of events in
the IL-1ra group.
Conclusion IL-1 drives C-reactive protein elevation at the time of NSTE-ACS. Following 14 days IL-1ra treatment inflammatory
markers were reduced. These results show the importance of IL-1 as a target in ACS, but also indicate the need for
additional studies with anti-IL-1 therapy in ACS to assess duration and safety.
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Introduction
Acute coronary syndromes (ACSs) are common conditions that
account for about 15%of all deaths and cause considerablemorbidity
among survivors. Coronary plaque destabilization, and thus presen-
tation of ACS, is associated with inflammation in the vessel wall1–3
and a systemic inflammatory response. However, it is unknown
whether specific anti-inflammatory treatmentsmodify ACS-associated
inflammation and subsequent clinical events.
Interleukin-1 (IL-1) is a cytokine at the start of the innate inflamma-
tory response, released mainly from macrophages and monocytes,
which transduces signals from bacterial products through pattern
recognition receptors, complement activation, and TNFa.4 IL-1 is
implicated in arterial wall inflammation in atherosclerosis and is
viewed as a therapeutically tractable system. IL-1 is expressed in
the vessels of humans with coronary atherosclerosis.5,6 Vessel wall
IL-1 increases after balloon injury,7 and inhibition of IL-1 is associated
with reduced neointima formation in a variety of experimental
models.8 In Apo-E deficient mice interleukin-1 receptor antagonist
(IL-1ra) inhibits the formation of intimal fatty streaks9 and genetic de-
letion of the IL-1 receptor is associated with a reduction in athero-
sclerosis in response to fat feeding.10
C-reactive protein rises followingACS and elevation of C-reactive
protein is associated with future cardiovascular events.11–16 IL-1
induces IL-6 production,16 both of which stimulate hepatocyte
production of C-reactive protein. Serum levels of IL-6 are elevated
in patients with ACS17 and an elevation is an independent marker
of increased mortality in ACS.18 Thus IL-1 may act as a driver of
ACS and the associated inflammatory response. IL-1 signalling can
be blocked in man by human recombinant IL-1 receptor antagonist
(IL-1ra).4 The main objective of this study was to examine the
effect of IL-1ra given for 14 days upon high-sensitive C-reactive
protein levels in patients with non-ST elevation ACS (NSTE-ACS).
Methods
Study design
The aims and methods of the MRC ILA Heart Study have been
described in detail previously and the protocol and statistical analysis
plan are available in the online appendix.19 The protocol and statistical
analysis plan are available in the online appendix. In brief, this was a ran-
domized, double blind, placebo-controlled multi-centre clinical trial
evaluating the effect of a 14-day regimen of IL-1ra on high-sensitive
C-reactive protein level after NSTE-ACS. Additional outcomes of inter-
est were levels of von Willebrand factor (vWF), IL-6, troponin, infarct
size estimated by cardiac magnetic resonance (CMR) and burden of is-
chaemia by continuous ECG monitoring. Patients were recruited from
five UK hospitals from the cardiac and medical admission wards. The
study protocol complies with the Declaration of Helsinki. Ethical ap-
proval was obtained from the nationally approved Leeds West Re-
search Ethics Committee and each centre obtained local specific
ethical approval. All patients gave fully informed written consent to par-
ticipate. The study complied with regulatory requirements of the Euro-
pean Union. Adverse events were reviewed by experienced staff
blinded to treatment allocation to verify classification and potential as-
sociation with treatment. An independent data safety monitoring board
reviewed safety data throughout the study.
Participants
Eligible patients had typical cardiac chest pain,48 h fromonset of symp-
toms, ECG changes of ischaemia, and an elevated troponin prior to ran-
domization. The main exclusion criteria were ST elevation on the ECG,
need for immediate reperfusion, or prior revascularization.
Randomization and masking
Eligible patients were randomly assigned in a 1:1 ratio using a central 24 h
telephone system, stratified by study centre to receive either a 14-day
supply of the recombinant IL-1ra Anakinra (KineretTM from Amgen) or
matching placebo. Qualified research personnel were masked to treat-
ment and remained so from the time of randomization. Patients were
taught to administer their own injections, but in cases where this was
not possible, injections were administered by health professionals or
trained family members.
Procedures
After randomization, either 100 mg of Anakinra or 100 mg of placebo
was injected subcutaneously once daily in the morning into the
abdomen or thigh. Other drugs were left to the treating physicians’ dis-
cretion. Blood was drawn prior to the injection of study drug at the
same time each day (+2 h), daily for 7 days and then at Days 14 and
30. Measurements were: high-sensitive C-reactive protein at baseline,
Days 1–7, 14, and 30; troponin and full blood count at baseline, 1–7,
and Day 14; creatinine, electrolytes, liver function tests at baseline,
Days 1–7 and 14; IL-6 and vWF at baseline, Days 1–3, Days 14 and 30.
Patientswere followed-up for30days. Formeasurementof high-sensitive
c-reactive protein, troponin, Vwf, and IL-6, blood samples were pro-
cessed and then frozen at 2808C before transportation on dry ice in
batches to the core laboratories.
ST Holter Monitor Sub-study: between Days 2 and 4 post-
randomization, patients at one centre (Sheffield) underwent three lead,
continuous ECG monitoring for 24 h. These were analysed by an auto-
mated algorithm for ST-segment deviation, and independently reviewed
by a blinded cardiac physiologist and a physician (see Supplementary ma-
terial online). Cardiac Magnetic Resonance Sub-study: Patients at one
centre (Leeds) were scheduled for baseline CMR imaging during their
index admission with a follow-up study at 30 days, using an identical
imaging protocol (see Supplementary material online).
The primary endpoint was the log-transformed area-under-the-curve
(AUC) of serum high-sensitive C-reactive protein over the first 7 days.
Secondary endpoints included high-sensitive C-reactive protein at 7,
14, and 30 days, log transformed AUC of Troponin-I, vWF and IL-6,
total duration of ST-segment depression onHolter monitoring, myocar-
dial scar, area at risk, and left-ventricular function determined by CMR.
The cumulative incidence of major adverse cardiovascular events
(MACE) including death, stroke, and new myocardial infarction were
recorded at 30 days, 3 months, and 12 months.
Sample size and statistical analysis
To detect a relative reduction of one-third in the high-sensitive
C-reactive protein AUC between the treatment and the placebo
groups, which was the reduction seen in IL-1ra treatment of rheumatoid
arthritis at this dose (Amgen data on file), with 80%power at a 5% level of
significance required 80 patients in each group (n ¼ 160) based upon the
log-transformed value of the area under the curve of high-sensitive
C-reactive protein and a standardized difference [difference/ standard
deviation (D)] of 0.45. To allow for data loss of 10% in each arm and
two interim analyses, a final sample size of 184 patients was projected
with a P-value of ,0.045 considered significant.20 Patients with at least
four follow-up measurements of high-sensitive C-reactive protein were
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included in the primary analysis on an intention-to-treat basis andmissing
datawas imputedusing aMarkovChainMonteCarlo (MCMC) simulation
method.21 A Student’s t-test was used to estimate the treatment effect
(in form of geometric mean ratios) for the primary endpoint and some
secondary endpoints. The time-to-event endpoints were compared
using the log-rank test. Other serious adverse events were analysed
using a Fisher exact test. All analyses were done using Stata version
10.1 and SAS version 9.1.3.
Results
A total of 182 patients (93 IL-1ra treated, 89 placebo)were recruited
at five UK centres between July 2007 and March 2010 and followed
for 1 year. Patient flow through the study is summarized in
Figure 1.19 Baseline characteristics were well matched between the
two groups (Table 1). The mean age was 61 years, there was an
excess of males, and 26% had prior MI. In-hospital revascularization
Figure1 Consort flowdiagramdetailing the numberof participantswhowere randomlyassigned and followed-up for the durationof the study up
to 1 year.
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rates were similar between groups (Table 4). The patients were well
treated with contemporary therapy; at 14 days 95% were taking
aspirin, 90% clopidogrel, 95% statins, and 80% ACE-inhibitors or
angiotensin receptor blockers. Patients were randomized within
48 h from onset of chest pain and there was no difference in time
from onset of chest pain to first dose between group (see Supple-
mentary material online). In total, 85% of patients in the IL-1ra
groupand84% in theplacebogroupreceivedall 7 daily dosesof treat-
ment and 81 and 84%, respectively, continued treatment up to 14
days (all comparisons non-significant). Over two-thirds of patients
successfully self-injectedmedication upondischarge home (nodiffer-
ence between groups), the remaining patients medication being
administered by the nursing team. The reasons for non-compliance
to treatment are shown in the Supplementary material online.
As pre-specified in the statistical analysis plan, only patients with
four or more readings of high-sensitive C-reactive protein were
included in the primary outcome analysis. Ten patients in the IL-1ra
group and 12 in the placebo group had ,4 readings, these patients
were excluded from the primary outcome analysis. high-sensitive
C-reactive protein over the first 7 days are shown in Figure 2. high-
sensitive C-reactive protein levels were similar on the first 2 days
of treatment but then diverged with suppression in the IL-1ra
group. The high-sensitive C-reactive protein AUC for the first 7
days in the IL-1ra group was 21.98 mg day/L (95%CI 16.31–29.64)
and 43.50 mg day/L (31.15–60.75) in the placebo group, with the
geometric mean ratio between IL-1ra and placebo being 0.51 (95%
CI: 0.32–0.79), P ¼ 0.0028 (Table 2 and Figure 2). This suggests that
IL-1ra reduced high-sensitive C-reactive protein AUC by almost
half over the first 7 days. The significant difference in absolute
levels seen at Day 7 was maintained at Day 14. Table 3 shows
routine blood results at baseline andDay 14. Therewas a statistically
significant suppression of white cell count throughout treatment but
no overt neutropaenia.
At Day 30, an increase in the absolute high-sensitive C-reactive
protein from Day 14 in the IL-1ra treated group to 3.50 mg/L
(2.65–4.62) was seen. This is in contrast to placebo treatment
where high-sensitive C-reactive protein continued to decline to
2.21 mg/L (1.67–2.92). This resulted in a significant difference
between groups at Day 30.
There were no differences in troponin AUC (Days 1–7) or any
absolute measures of troponin (see Supplementary material online,
Figure). The AUC of IL-6 (Days 1–3) in the IL-1ra group
was 8.24 pg day/mL (6.71–0.11) and in the placebo group was
12.32 pg/mL (9.66–15.73) P ¼ 0.012. IL-6 levels remained suppressed
by IL-1ra at Day 14 but by Day 30 there was no significant difference
between groups. There were no significant differences in any vWF
measurements.
Clinical outcomes, MACE, and adverse events are summarized in
Table 4 and Figure 3. As expected, there was a significant increase in
injection site reactions in the IL-1ra treated group (26 compared
with 4% with placebo, P, 0.0001). There was no significant differ-
ence in MACE at 30 days or 3 months. Although this study was not
powered for the analysis of clinical outcomes, at 1 year there was a
significant increase in MACE in the IL-1ra treated group, driven by a
non-significant increase in recurrent myocardial infarction.
There were no significant differences between groups in either of
the ST segment Holter or CMR sub-studies (see Supplementary
material online).
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Table 1 Baseline characteristics of patients
Variable Active
(n 5 93)
Placebo
(n 5 89)
P-value
Age (years), mean (SD) 61.4 (11.7) 61.3 (12.3) 0.9556
Male, n (%) 63 (67.7) 67 (75.3) 0.3249
White British, (%) 89 (95.7) 82 (92.1) 0.6845
BMI (kg/m2) 30.0 (7.1) 28.4 (4.7) 0.0687
SBP (mmHg) 131.4 (20.7) 126.5 (16.7) 0.0795
DBP (mmHg) 75.2 (12.5) 74.3 (11.3) 0.6063
Current smoking, n (%)
Current 34 (36.6) 31 (34.8) 0.4140
Ex 34 (36.6) 27 (30.3)
Never 24 (25.8) 31 (34.8)
NA 1 (1.1) 0 (0)
Previous MI, n (%) 23 (24.7) 24 (27.0) 0.9313
Prior stroke, n (%) 1 (1.1) 3 (3.4) 0.3600
Prior TIA, n (%) 8 (8.6) 2 (2.2) 0.0769
Family history of IHD, n (%) 48 (51.6) 47 (52.8) 1.0000
Hypertension, n (%) 31 (33.3) 29 (32.6) 1.0000
Hyperlipidaemia, n (%) 27 (29.0) 28 (31.5) 0.9344
IDDM, n (%)
Insulin dependent 2 (2.2) 2 (2.2) 0.0876
Non-insulin dependent 7 (7.5) 6 (6.7)
Diet controlled 6 (6.5) 0 (0)
No history 77 (82.8) 81 (91.0)
NA 1 (1.1) 0 (0)
NA, not applicable; MI, myocardial infarction.
Figure 2 Geometric mean of high sensitivity C-reactive protein
over the first 7 days of treatment with IL-1ra or placebo (95% CI)
calculated for primary outcome analysis.
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Table 2 Primary and secondary outcome results
Outcome Active Placebo Treatment effect
n GM (95% CI) n GM (95% CI) GM Ratio (95% CI) P-value
Imputed high-sensitive C-reactive protein
AUC (Days 1–7, mg.day/L)a
83 21.98 (16.31, 29.64) 77 43.50 (31.15, 60.75) 0.51 (0.32, 0.79) 0.0028
High-sensitive C-reactive protein at Day 1 (mg/L) 89 5.38 (4.12, 7.04) 85 5.21 (3.75, 7.22) 1.03 (0.68, 1.57) 0.88
High-sensitive C-reactive protein at Day 7 (mg/L) 77 1.53 (1.12, 2.11) 71 6.77 (4.92, 9.31) 0.25 (0.15, 0.35) ,0.0001
High-sensitive C-reactive protein at Day 14 (mg/L) 80 1.74 (1.28, 2.39) 73 4.60 (3.21, 6.59) 0.38 (0.24, 0.61) 0.0001
High-sensitive C-reactive protein at Day 30 (mg/L) 78 3.50 (2.65, 4.62) 74 2.21 (1.67, 2.92) 1.58 (1.07, 2.34) 0.022
Imputed troponin AUC (Days 1–7, mg.day/L) 83 3.23 (2.15, 4.87) 77 3.83 (2.46, 5.96) 0.84 (0.46, 1.54) 0.58
Troponin at Day 1 (mg/L) 89 0.97 (0.63, 1.49) 85 1.25 (0.79, 1.97) 0.77 (0.41, 1.45) 0.42
Troponin at Day 7 (mg/L) 77 0.12 (0.08, 0.18) 71 0.14 (0.09, 0.23) 0.83 (0.43, 1.56) 0.55
Troponin at Day 14 (mg/L) 80 0.025 (0.017, 0.036) 73 0.026 (0.016, 0.041) 0.96 (0.54, 1.69) 0.88
Troponin at Day 30 (mg/L) 79 0.014 (0.001, 0.021) 74 0.012 (0.007, 0.018) 1.23 (0.71, 2.11) 0.46
Imputed vWF AUC (Days 1–3, IU.day/mL) 89 2.98 (2.75, 3.22) 84 3.04 (2.83, 3.27) 0.98 (0.88, 1.09) 0.68
vWF at Day 1 (IU/mL) 90 1.45 (1.34, 1.56) 84 1.43 (1.32, 1.54) 1.01 (0.91, 3.39) 0.80
vWF at Day 14 (IU/mL) 81 1.35 (1.24, 1.47) 74 1.41 (1.29, 1.54) 0.96 (0.85, 1.08) 0.48
vWF at Day 30 (IU/mL) 80 1.39 (1.28, 1.51) 72 1.38 (1.26, 1.53) 1.01 (0.89, 1.14) 0.92
Imputed IL-6 AUC (Days 1–3, pg.day/mL) 87 8.24 (6.71, 10.11) 82 12.32 (9.66, 15.73) 0.67 (0.49, 0.92) 0.012
IL-6 at Day 1 (pg/mL) 86 6.01 (4.68, 7.72) 81 5.23 (3.98, 6.88) 1.15 (0.80, 1.66) 0.45
IL-6 at Day 14 (pg/mL) 76 2.51 (2.04, 3.08) 70 3.82 (2.82, 5.16) 0.66 (0.46, 0.94) 0.022
IL-6 at Day 30 (pg/mL) 77 3.38 (2.80, 4.16) 71 2.88 (2.38, 3.49) 1.18 (0.90, 1.56) 0.22
aPrimary outcome excludes patients with ,4 high-sensitive C-reactive protein readings.
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Table 3 Routine blood results at baseline and Day 14
Variable Baseline Day 14
Active (n5 93) Placebo (n5 89) P-value Active (n 5 85) Placebo (n5 79) P-value
Haemogloblin (g/dL) 14.18+1.46 14.31+1.44 0.54 13.65+1.41 13.35+1.48 0.19
White cell count (×109/L) 9.16+2.61 8.87+2.35 0.44 7.13+1.70 7.78+1.91 0.027
Platelets (×109/L) 266.92+63.77 269.70+99.44 0.82 268.81+75.18 299.17+86.91 0.022
Urea (mmol/L) 5.56+1.76 5.43+1.89 0.64 6.19+2.25 5.39+2.21 0.028
Creatinine (mmol/L) 91.14+17.71 92.05+24.91 0.78 96.59+20.59 93.42+25.18 0.40
Sodium (mmol/L) 138.07+2.98 138.00+2.96 0.88 138.89+3.05 138.24+3.80 0.25
Potassium mmol/L) 4.16+0.32 4.22+0.37 0.29 4.39+0.28 4.45+0.40 0.32
eGFR (mL/min) 73.36+15.86 75.06+21.20 0.55 69.96+15.48 74.25+19.71 0.14
Aspartate transaminase (IU/L) 35.30 (30.74, 40.53) 36.56 (30.97, 43.15) 0.74 25.82 (23.73, 28.10) 22.51 (20.86, 24.29) 0.02
Alkaline transaminase (IU/L)a 26.34 (23.66, 29.32) 25.92 (23.39, 28.73) 0.83 29.09 (25.91, 32.67) 23.64 (21.48, 26.02) 0.007
Alkaline phosphatise (IU/L)a 96.77 (86.02, 108.88) 88.27 (78.80, 98.88) 0.27 88.93 (78.27, 101.04) 88.80 (77.75, 101.42) 0.99
Total bilirubin (mmol/L) 11.04 (10.05, 12.13) 12.28 (11.07, 13.62) 0.13 11.11+4.99 10.71+5.34 0.65
CK (IU/L) 147.28 (110.46, 196.36) 199.04 (156.50, 253.14) 0.11 – – –
CKMB (mg/L)a 5.44 (3.57, 8.28) 4.83 (3.01, 7.78) 0.71 – – –
Troponin I (mg/L)a 1.40 (0.94, 2.10) 2.42 (1.58, 3.71) 0.07 – – –
Troponin T (mg/L)a,b 0.15 (0.05, 0.52) 0.27 (0.11, 0.67) 0.39 – – –
aGeometric mean (95% CI).
bn ¼ 17; 8 active, 9 placebo.
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Discussion
This is the first randomized trial to investigate the effects of a specific
inhibitor of interleukin-1 (IL-1ra, Anakinra) in the NSTE-ACS and
demonstrates powerful suppression of markers of inflammation in
this condition. Widespread coronary inflammatory activation has
become the established mechanism of ACS.22,23 The link between
this paradigm and blood-basedmarkers of inflammation has been sug-
gested by a number of studies, often based on secondary analysis of
large trials of a variety of therapeutic compounds,12 and a 30- patient
pilot study investigating the effect of IL-1RA on cardiac remodelling
post-STEMI showed a significant reduction in high-sensitiveC-reactive
protein at 72 h.24 These studies have suggested that relative elevations
of high-sensitiveC-reactive protein, IL-6, and vWF, amongothers,may
predict a number of adverse outcomes plausibly linked to continued
coronary inflammation.12,17,18,25 Prospective studies are based
mainly in the stable populationwhere small elevationsof high-sensitive
C-reactive protein appear to predict continued risk of AMI and other
CV events although this effect may be small.15,26 Others, looking
specifically at the time of ACS, have not seen a predictive property
of high-sensitive C-reactive protein.27
This study indicates that IL-1 drives a significant part of the eleva-
tion of high-sensitive C-reactive protein that occurs at the time of
NSTE-ACS. The study has examined the treatment effect on high-
sensitive C-reactive protein in two ways: the AUC of high-sensitive
C-reactive protein (up to Day 7) reflecting total high-sensitive
C-reactive protein production in this time, and achieved high-
sensitive C-reactive protein at Day 14 (patients were prepared to
self-inject for 14 days, but had daily samples drawn for only 7
days). high-sensitive C-reactive protein was rapidly suppressed
into the normal range in treated patients and was persistently
lower than in the control group for the duration of therapy with
IL-1ra. Since, IL-1ra has no known functions other than blockade
of the IL-1 signalling receptor and is highly effective therapy in IL-1
driven auto-inflammatory syndromes, these data strongly suggest
the importance of IL-1 as a driving influence on inflammation in
these patients.
At the time of discontinuation of IL-1ra at 14 days high-sensitive
C-reactiveproteinwas suppressed, suggesting inhibitionof inflamma-
tion, but by Day 30, high-sensitive C-reactive protein levels rose in
the IL-1ra treated group, whereas those in the placebo group contin-
ued to fall resulting in a significant difference between the groups at
30 days. This indicates a loss of the IL-1ra mediated inhibition of
inflammation. These results suggest that either the inflammatory
events around the time of NSTE-ACS may continue beyond Day
14 and/or that IL-1-stimulated inflammation may normally drive its
own later resolution. Both explanations are plausible. IL-1 receptor
occupation leads to a number of events that are associated with
either latent IL-1 expression that is not translated or IL-1 production
that is not released. It is also possible thatwithdrawal of IL-1 receptor
inhibition leads to increased sensitivity to IL-1 via the loss of endogen-
ous IL1-ra normally driven by IL-1 receptor stimulation.
IL-1ra therapy was in general very well tolerated. There was the
expected increase in injection site reactions with the treatment and
a mild but significant lowering of the white cell count, which is pre-
sumably the withdrawal of IL-1 mediated white cell survival
effects.28 This study was not powered for clinical endpoints,
however, the MACE composite endpoint at 1 year showed an in-
crease in events in the IL-1ra-treated group. This may be for a
number of reasons including pharmacological issues (dose and dur-
ation of therapy), or biological consequences of IL-1 inhibition that
impairs natural healing driving the late MACE, but this will need to
be explored in other appropriately designed studies. Considerable
caution, however, should be given to the validity of these MACE
observations because of power limitations.
IL-1ra therapy was without effect upon infarct size, as measured
by troponin and CMR (see Supplementary material online). There
is debate from studies using experimental models of the effect of
IL-1 inhibition on infarct size. Our results do not support a reduction
in infarct size by IL-1ra in the NSTE-ACS patients we studied, but do
not exclude either an effect in more extensive or full-thickness myo-
cardial infarction as may occur in ST elevation ACS. The findings
suggest that the effects of IL-1ra are not due to a reduction in
infarct size but there is a reduction of the associated inflammation.
Whether the inflammatory stimulus derives from the plaque or the
myocardium is unknown and unexplored in this study.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Summary statistics for analysis of MACE and
other serious adverse events
Parameter Active
(n 5 93)
Placebo
(n 5 89)
P-value
Time-to-event analysisa
MACE at 30 days 3 (46.4) 2 (32.2) 0.6800
MACE at 3 months 7 (38.0) 2 (10.7) 0.0980
MACE at 1 year 13 (18.9) 4 (5.4) 0.0233
Death 5 (6.8) 2 (2.7) 0.2440
MI 8 (11.4) 2 (2.7) 0.0581
Stroke 1 (1.3) 0 (0.0) 0.3205
Event analysisb
All bleeds 2 (2.2) 1 (1.1) 1.0000
Neutropaenia 0 (0.0) 0 (0.0) NA
Serious infection 2 (2.2) 1 (1.1) 1.0000
Revascularization 84 (90.3) 76 (85.4) 0.3664
Any (-cath only) 60 (64.5) 54 (60.7) 0.6468
CABG only 3 (3.2) 1 (1.1) 0.6212
Cath and CABG 4 (4.3) 5 (5.6) 0.7431
Cath and PCI 53 (57.0) 48 (53.9) 0.7656
PCI only 1 (1.1) 0 (0.0) 1.0000
Cath only 28 (30.1) 26 (29.2) 1.0000
Injection site
reactions
24 (25.8) 4 (4.5) ,0.0001
Other SAE 30 (32.3) 21 (23.6) 0.2478
Cardiac 19 (20.4) 14 (15.7) 0.4463
Non-cardiac 15 (16.1) 7 (7.9) 0.1120
Unable to specify 2 (2.2) 5 (5.6) 0.2704
MACE, major adverse cardiovascular event; NA, not applicable.
aP-value was calculated from log-rank test. Number of patients with events
(incidence rate/100) is presented.
bP-valuewas calculated fromFisher exact test.Number of patientswith events (%) is
presented.
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This study has some important limitations, which have become ap-
parent given the results. Themost obvious is that treatmentwas given
for only one duration—14 days—and our data suggest that a longer
duration would have been be desirable. The treatment was given as
early as possible but as this was a trial requiring consent, we cannot
excludeadifference in results if the IL-1rahadbeengiven immediately
by the study team. The size of infarcts is certainly not large, as shown
in theCMRsubstudy.Abigger infarctmayhave givenmoreopportun-
ity for an effect on infarct size modulation. The study was not
powered for late events and as a result we have very few details on
the nature of these late events that give rise to the apparent excess
MACE at 1 year.
These results, therefore, give both encouragement and potential
warning for the use of IL-1 inhibition in patients with coronary
artery disease that has presented as ACS. We show that IL-1 is cer-
tainly an important mediator of the inflammation at the time of
NSTE-ACS and this trial met its primary endpoint. The duration of
treatment and perhaps dose and timing of treatment with this inhibi-
tor inACSmay, however, be critical. These results indicate that treat-
ment for 14 days is insufficient to achieve durable suppression of
inflammation following discontinuation of the drug. Our results
have also indicated the possibility of an increased rate of late
re-infarction following a 2-week period of IL-1 inhibition. This
demands further study as IL-1 is so clearly an important mediator
in ACS as shown by our results. The large prospective study of long-
term IL-1 inhibition inpatientswithCAD in theCANTOS29 studywill
throw more light on this important area, but additional studies
around the time of ACS are now urgently needed.
Statement on analysis error
of this manuscript
In July 2010, the preliminary results for the MRC-ILA-HEART Study
were prepared and disseminated to authors for review. TheChief In-
vestigator queried the results on the basis of the equivalence of injec-
tion site reaction rate with the Clinical Trials and Evaluation Unit
(CTEU) in September 2010, which was re-checked and verified by
the study statistician. A manuscript was subsequently prepared but
was never published. In July 2012, the Chief Investigator requested
an audit of the study results, which was undertaken in August 2012.
This identified a simple yet critical error in the linkage of the
Figure 3 Kaplan–Meier event curves for major adverse cardiovascular events, death, myocardial infarction, and stroke by treatment.
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randomization list with the patient ID list which produced an incor-
rect result. When the analysis was repeated with the correct data,
the primary endpoint of the trial had been met as reported here.
An abstract of the incorrect data was published (http://heart.bmj
.com/content/97/Suppl_1/A13.1) but the error has been notified
by Heart.
A subsequent investigation led by the Chair of the trial Data Mon-
itoring Committee in August 2012 confirmed the simple but critical
error in the linkagewith the randomization list and recommended the
re-analysis of the data by the study statistician and also an independ-
ent re-analysis by a second statistician. The Trial SteeringCommittee
in a meeting in November 2012 endorsed this course of action.
Therefore, D.W. was appointed to conduct an independent analysis
of the data. The findings of D.W. were consistent with the revised
analysis by the study statistician and it is this verified data that is
reported in this manuscript.
Supplementary material
Supplementary material is available at European Heart Journal online.
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